By Dr Louise Emmett

Book Chapters

Emmett L, 2022, 'Side effects of therapy with radiolabelled prostate specific membrane antigen (PSMA)', in Nuclear Medicine and Molecular Imaging Volume 1 4, pp. 214 - 219, http://dx.doi.org/10.1016/B978-0-12-822960-6.00150-2

Wong T; Girgis CM; Ngu MC; Chen RCY; Emmett L; Archer KA; Seibel MJ, 2011, '13. A 40-year-old Man with Widespread Bone Pain', in Diagnostic Dilemmas: Images in Endocrinology, The Endocrine Society, pp. 74 - 78, http://dx.doi.org/10.1210/dde1.9781936704583.ch13

Emmett L, 2004, 'Vascular Manifestations. Chapter 48.', in Nuclear medicine in clinical diagnosis and treatment., pp. 693 - 707

Journal articles

Kwan EM; Ng SWS; Tolmeijer SH; Emmett L; Sandhu S; Buteau JP; Iravani A; Joshua AM; Francis RJ; Subhash V; Lee S-T; Scott AM; Martin AJ; Stockler MR; Donnellan G; Annala M; Herberts C; Davis ID; Hofman MS; Azad AA; Wyatt AW; TheraP Investigators and the ANZUP Cancer Trials Group , 2025, 'Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.', Nat Med, http://dx.doi.org/10.1038/s41591-025-03704-9

Sabahi Z; Nguyen A; Wong K; Li S; Papa N; Lim E; Dear RF; Menzies AM; Boyle F; Antill Y; Kiely BE; Forster BC; Mak C; Adams D; Pugliano L; Spillane A; Sharma S; Hickey A; Poole A; Agrawal S; Khan S; Ayati N; Emmett L, 2025, 'Diagnostic Potential of 68Ga-NeoB PET/CT with Estrogen Receptor– and Progesterone Receptor–Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease', Journal of Nuclear Medicine, 66, pp. 700 - 706, http://dx.doi.org/10.2967/jnumed.124.268896

Chen DC; Huang S; Papa N; Siva S; Bolton DM; Lawrentschuk N; Emmett L; Murphy DG; Hofman MS; Perera ML, 2025, 'Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis', BJU International, 135, pp. 720 - 732, http://dx.doi.org/10.1111/bju.16608

Chen DC; Buteau JP; Emmett L; Alipour R; de Galiza Barbosa F; Roberts MJ; McVey A; O’Brien J; Levy S; Francis RJ; Lawrentschuk N; Murphy DG; Hofman MS, 2025, 'Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study', Journal of Nuclear Medicine, 66, pp. 713 - 718, http://dx.doi.org/10.2967/jnumed.124.268901

Kostos L; Buteau JP; Kong G; Tran B; Haskali MB; Fahey M; Crumbaker M; Emmett L; Hofman MS; Azad AA, 2025, 'Clinical Trial Protocol for LuCAB: A Phase I–II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer', Journal of Nuclear Medicine, 66, pp. 572 - 578, http://dx.doi.org/10.2967/jnumed.124.269252

Eifer M; Sutherland DEK; Goncalves I; Buteau JP; Au L; Azad AA; Emmett L; Kong G; Kostos L; Ravi Kumar AS; Kwan EM; Medhurst E; Sandhu S; Tran B; Wyatt AW; Hofman MS, 2025, 'Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series', Journal of Nuclear Medicine, 66, pp. 579 - 584, http://dx.doi.org/10.2967/jnumed.124.268640

Emmett L; Subramaniam S; Crumbaker M; Joshua AM; Sandhu S; Nguyen A; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Kumar ASR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; McJannett M; Thomas H; Langford A; Hofman MS; Martin AJ; Davis ID; Stockler MR; Nguyen A; Ravi Kumar AS; Lin P; Butler P; Martin AJ; Zebic D; Mak B; Tankard N; Rana N; Cusick T; Thompson J; Oakes S; Niu C; Thein T; Ford K; Ristevski N; Yip S; Bills M, 2025, 'Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial', Lancet Oncology, 26, pp. 291 - 299, http://dx.doi.org/10.1016/S1470-2045(25)00009-9

Warrender-Sparkes M; Tomaszewski JM; Ip C; Chander S; Christie D; Corcoran NM; Emmett L; Finnigan R; Hayden A; Higgs B; Horsley P; Holt T; Sasso G; Shakespeare TP; Sidhom M; Tree A; Kneebone A, 2025, 'Post-prostatectomy radiation therapy: Updated guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group (FROGG)', Radiotherapy and Oncology, 204, http://dx.doi.org/10.1016/j.radonc.2024.110690

Emmett L, 2025, 'SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics Therapy', Journal of Nuclear Medicine, 66, pp. 349 - 350, http://dx.doi.org/10.2967/jnumed.124.268325

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Sandhu S; Zhang AY; Hofman MS; Thomas H; Martin AJ; Davis ID; Stockler MR, 2025, 'Overall survival and quality of life with [ ¹⁷⁷ Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).', Journal of Clinical Oncology, 43, pp. 17 - 17, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.17

Sollini M; Calais J; Chiti A; Emmett L; Fanti S; Fendler W; Herrmann K; Hope TA; Sartor O; Shuch B; Tagawa S; Hofman MS, 2025, 'Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers', European Urology, 87, pp. 125 - 139, http://dx.doi.org/10.1016/j.eururo.2024.09.036

Gafita A; Martin AJ; Emmett L; Eiber M; Iravani A; Fendler WP; Buteau J; Sandhu S; Azad AA; Herrmann K; Stockler MR; Davis ID; Hofman MS, 2025, 'Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial', European Urology Oncology, 8, pp. 21 - 28, http://dx.doi.org/10.1016/j.euo.2024.03.009

Bahadori A; Woods J; Yuan L; Emmett L; Yaxley J; Roberts MJ, 2025, 'Biopsy-free radical prostatectomy: a narrative review considering rationale, limitations, and current data', Prostate International, http://dx.doi.org/10.1016/j.prnil.2025.03.003

Emmett L; Zheng A; Jin C; Papa N; Khan S; Ayati N; Susman T; Ngai K; Nelson A; Sharma S; Anand R; John N; Crumbaker M; Nguyen A; Herrmann K, 2025, '‘One button push’ fully automated PSMA PET quantification: Correlation with progression free and overall survival in patients undergoing [ ¹⁷⁷ Lu] Lu PSMA therapy for metastatic castrate resistant prostate cancer.', Journal of Clinical Oncology, 43, pp. 5054 - 5054, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5054

Sandhu S; Subramaniam S; Thomas H; Tan TH; Goh JC; Dhiantravan N; Weickhardt AJ; Joshua AM; Kirkwood ID; Lee ST; Gedye C; Nguyen A; Pattison DA; Alipour R; Francis RJ; Hofman MS; Martin AJ; Stockler MR; Davis ID; Emmett L, 2025, '¹⁷⁷ Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001).', Journal of Clinical Oncology, 43, pp. 5016 - 5016, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5016

Medici F; Aebersold DM; Casuscelli J; Emmett L; Fanti S; Farolfi A; Fendler W; Guckenberger M; Hruby G; Koerber SA; Kroez S; Peeken JC; Rogowski P; Scharl S; Shelan M; Spohn SKB; Strouthos I; Unterrainer L; Vogel M; Wiegel T; Zamboglou C; Schmidt-Hegemann N-S; Morganti AG; Cilla S, 2025, '3878 Machine learning integration for prognostic modeling in PSMA-PET-driven salvage radiotherapy for biochemical recurrence post-prostatectomy', Radiotherapy and Oncology, 206, pp. S3851 - S3852, http://dx.doi.org/10.1016/s0167-8140(25)02025-0

Munzur AD; Herberts C; Kwan EM; Emmett L; Sandhu S; Buteau JP; Iravani A; Joshua AM; Francis RJ; Lee ST; Scott AM; Martin AJ; Stockler MR; Zhang AY; Williams SG; Bacon JVW; Azad A; Davis ID; Hofman MS; Wyatt AW, 2025, 'Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving ¹⁷⁷ Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).', Journal of Clinical Oncology, 43, pp. 5020 - 5020, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5020

Emmett L; Papa N; Subramaniam S; Crumbaker M; Joshua AM; Nguyen A; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Hofman MS; Sandhu S; Martin AJ; Thomas H; Davis ID; Stockler MR, 2025, 'Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ ¹⁷⁷ Lu] Lu-PSMA-617 (ANZUP1901).', Journal of Clinical Oncology, 43, pp. 5011 - 5011, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5011

Sabahi Z; Papa N; Fendler WP; Nguyen A; Wong K; Ayati N; Ho B; Chen J; Cusick T; Burger I; Crumbaker M; Marx GM; Sharma S; Frydenberg M; Sandhu S; Davis ID; Stockler MR; Sweeney C; Joshua AM; Emmett L, 2025, 'Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.', Journal of Clinical Oncology, 43, pp. 5091 - 5091, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5091

Swiha M; Pathmanandavel S; Papa N; Sabahi Z; Li S; Zheng A; Khan S; Ayers M; Sharma S; Crumbaker M; Nguyen A; Chan L; Ayati N; Emmett L, 2024, 'Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer', Journal of Nuclear Medicine, 65, pp. 1939 - 1944, http://dx.doi.org/10.2967/jnumed.124.267606

Roberts MJ; Papa N; Veerman H; de Bie K; Morton A; Franklin A; Raveenthiran S; Yaxley WJ; Donswijk ML; van der Poel HG; Samaratunga H; Wong D; Brown N; Parkinson R; Gianduzzo T; Kua B; Coughlin GD; Oprea-Lager DE; Emmett L; van Leeuwen PJ; Yaxley JW; Vis AN, 2024, 'Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics', BJU International, 134, pp. 47 - 55, http://dx.doi.org/10.1111/bju.16482

Murphy DG; Emmett L, 2024, 'PSMA PET Staging is Advised for All High-Risk Patients With Localized Prostate Cancer', International Journal of Radiation Oncology Biology Physics, 120, pp. 642 - 645, http://dx.doi.org/10.1016/j.ijrobp.2024.06.031

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6

Trapp C; Aebersold DM; Belka C; Casuscelli J; Emmett L; Eze C; Fanti S; Farolfi A; Fendler W; Grosu AL; Guckenberger M; Hruby G; Kirste S; Koerber SA; Kroeze S; Peeken JC; Rogowski P; Scharl S; Shelan M; Spohn SKB; Strouthos I; Unterrainer L; Vogel M; Wiegel T; Zamboglou C; Schmidt-Hegemann NS, 2024, 'Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis', European Journal of Nuclear Medicine and Molecular Imaging, 51, pp. 3770 - 3781, http://dx.doi.org/10.1007/s00259-024-06802-x

Soon YY; Marschner IC; Schou M; Hofman MS; Emmett L; Davis ID; Stockler MR; Martin AJ, 2024, 'Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer', JAMA Network Open, 7, pp. e2433863, http://dx.doi.org/10.1001/jamanetworkopen.2024.33863

Li S; Nguyen A; Counter W; John NC; De Leon J; Hruby G; Joshua AM; Stricker P; Crumbaker M; Ayati N; Chan L; Sabahi Z; Swiha M; Kneebone A; Wong K; Liu V; Sharma S; Agrawal S; Emmett LM, 2024, 'Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT', Journal of Nuclear Medicine, 65, pp. 1371 - 1375, http://dx.doi.org/10.2967/jnumed.124.267881

Emmett L; Papa N; Hope TA; Fendler W; Calais J; Burger I; Eiber M; Barbato F; Moon D; Counter W; John N; Xue A; Franklin A; Thompson J; Rasiah K; Frydenberg M; Yaxley J; Buteau J; Agrawal S; Ho B; Nguyen A; Liu V; Lee J; Woo H; Hsiao E; Sutherland T; Perry E; Stricker P; Hofman MS; Kasivisvanathan V; Roberts M; Murphy D, 2024, 'Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer', Journal of Urology, 212, pp. 299 - 307, http://dx.doi.org/10.1097/JU.0000000000004010

Menzies AM; Lo SN; Saw RPM; Gonzalez M; Ch'ng S; Nieweg OE; Shannon KF; Ferguson PM; Lee J; Emmett L; Kapoor R; Rawson RV; Stretch JR; Thompson JF; Spillane AJ; Rizos H; Scolyer RA; Long GV, 2024, 'Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma', Annals of Oncology, 35, pp. 739 - 746, http://dx.doi.org/10.1016/j.annonc.2024.05.002

Ndlovu H; Mokoala KMG; Lawal I; Emmett L; Sathekge MM, 2024, 'Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals', Pet Clinics, 19, pp. 371 - 388, http://dx.doi.org/10.1016/j.cpet.2024.03.003

Swiha M; Gafita A; Nguyen A; Emmett L, 2024, 'Treatment Response Imaging in Prostate Cancer', Pet Clinics, 19, pp. 417 - 430, http://dx.doi.org/10.1016/j.cpet.2024.03.009

Kwan EM; Hofman MS; Ng SWS; Emmett L; Sandhu S; Buteau JP; Iravani A; Joshua AM; Francis RJ; Subhash V; Lee ST; Scott AM; Martin AJ; Stockler MR; Donnellan G; Annala M; Tolmeijer SH; Azad A; Davis ID; Wyatt AW, 2024, 'Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [¹⁷⁷Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).', Journal of Clinical Oncology, 42, pp. 5055 - 5055, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5055

Buteau JP; Moon D; Fahey MT; Roberts MJ; Thompson J; Murphy DG; Papa N; Mitchell C; De Abreu Lourenco R; Dhillon HM; Kasivisvanathan V; Francis RJ; Stricker P; Agrawal S; O'Brien J; McVey A; Sharma G; Levy S; Ayati N; Nguyen A; Lee SF; Pattison DA; Sivaratnam D; Frydenberg M; Du Y; Titus J; Lee ST; Ischia J; Jack G; Hofman MS; Emmett L, 2024, 'Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer', European Urology Oncology, 7, pp. 544 - 552, http://dx.doi.org/10.1016/j.euo.2023.11.008

Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L, 2024, 'Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes', Journal of Nuclear Medicine, 65, pp. 904 - 908, http://dx.doi.org/10.2967/jnumed.123.267014

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID, 2024, '[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial', Lancet Oncology, 25, pp. 563 - 571, http://dx.doi.org/10.1016/S1470-2045(24)00135-9

Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Koerber SA; Debus J; Peeken JC; Vogel MME; Kroeze SGC; Guckenberger M; Krafcsik M; Hruby G; Emmett L; Schmidt-Hegemann NS; Trapp C; Spohn SKB; Henkenberens C; Mayer B; Shelan M; Aebersold DM; Thamm R; Wiegel T, 2024, 'European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy', Radiotherapy and Oncology, 194, http://dx.doi.org/10.1016/j.radonc.2024.110215

Geboers B; Meijer D; Counter W; Blazevski A; Thompson J; Doan P; Gondoputro W; Katelaris A; Haynes AM; Delprado W; O'Neill G; Yuen C; Vis AN; van Leeuwen PJ; Ho B; Liu V; Lee J; Donswijk ML; Oprea-Lager D; Scheltema MJ; Emmett L; Stricker PD, 2024, 'Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy', BJU International, 133, pp. 14 - 22, http://dx.doi.org/10.1111/bju.16207

Geboers B; Scheltema MJV; Emmett L; Stricker PD, 2024, 'Reply to ‘Re: Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy’', BJU International, 133, pp. 25 - 26, http://dx.doi.org/10.1111/bju.16308

Kumar S; Crumbaker M; Emmett L, 2024, '“Unraveling the Hypocalcemic Response to 177Lu-Prostate-Specific Membrane Antigen Therapy,”', Journal of Nuclear Medicine, 65, pp. 333 - 334, http://dx.doi.org/10.2967/jnumed.123.266768

Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RDA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L, 2024, 'The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy', BJU International, 133, pp. 39 - 47, http://dx.doi.org/10.1111/bju.16158

Janbain A; Farolfi A; Guenegou-Arnoux A; Romengas L; Scharl S; Fanti S; Serani F; Peeken JC; Katsahian S; Strouthos I; Ferentinos K; Koerber SA; Vogel ME; Combs SE; Vrachimis A; Morganti AG; Spohn SKB; Grosu AL; Ceci F; Henkenberens C; Kroeze SGC; Guckenberger M; Belka C; Bartenstein P; Hruby G; Emmett L; Omerieh AA; Schmidt-Hegemann NS; Mose L; Aebersold DM; Zamboglou C; Wiegel T; Shelan M, 2024, 'A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET–Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study', Jmir Cancer, 10, http://dx.doi.org/10.2196/60323

Zamboglou C; Staus P; Wolkewitz M; Peeken JC; Ferentinos K; Strouthos I; Farolfi A; Koerber SA; Vrachimis A; Spohn SKB; Aebersold DM; Grosu AL; Kroeze SGC; Fanti S; Hruby G; Wiegel T; Emmett L; Hayoz S; Ceci F; Guckenberger M; Belka C; Schmidt-Hegemann NS; Ghadjar P; Shelan M, 2024, 'Better Oncological Outcomes After Prostate-specific Membrane Antigen Positron Emission Tomography–guided Salvage Radiotherapy Following Prostatectomy', European Urology Focus, http://dx.doi.org/10.1016/j.euf.2024.11.006

Oprea-Lager DE; MacLennan S; Bjartell A; Briganti A; Burger IA; de Jong I; De Santis M; Eberlein U; Emmett L; Fizazi K; Gillessen S; Herrmann K; Heskamp S; Iagaru A; Jereczek-Fossa BA; Kunikowska J; Lam M; Nanni C; O'Sullivan JM; Panebianco V; Sala E; Sathekge M; Sosnowski R; Tilki D; Tombal B; Treglia G; Tunariu N; Walz J; Yakar D; Dierckx R; Sartor O; Fanti S, 2024, 'European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer', European Urology, 85, pp. 49 - 60, http://dx.doi.org/10.1016/j.eururo.2023.09.003

Swiha M; Ayati N; Oprea-Lager DE; Ceci F; Emmett L, 2024, 'How to Report PSMA PET', Seminars in Nuclear Medicine, 54, pp. 14 - 29, http://dx.doi.org/10.1053/j.semnuclmed.2023.07.007

Hofman MS; Emmett L; Sandhu S; Iravani A; Buteau JP; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; Stockler MR; Williams SG; Martin AJ; Davis ID; Akhurst T; Alipour R; Bailey D; Banks P; Beaulieu A; Campbell L; Crumbaker M; Dhiantravan N; Hamid A; Haskali M; Hung T; Kong G; Lawrence N; Lewin J; McCarthy M; Moodie K; Murphy D; Nguyen A; Pook D; Ravi Kumar A; Roach P; Roselt P; Saghebi J; Schembri G; Spain L; Subramaniam S; Thang SP; Thomas P; Tran B; Wallace R; Yip S, 2024, 'Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial', Lancet Oncology, 25, pp. 99 - 107, http://dx.doi.org/10.1016/S1470-2045(23)00529-6

Emmett L; Papa N; Counter W; Calais J; Barbato F; Burger I; Eiber M; Roberts MJ; Agrawal S; Franklin A; Xue A; Rasiah K; John N; Moon D; Frydenberg M; Yaxley J; Stricker P; Wong K; Coughlin G; Gianduzzo T; Kua B; Ho B; Nguyen A; Liu V; Lee J; Hsiao E; Sutherland T; Perry E; Fendler WP; Hope TA, 2024, 'Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database', Journal of Nuclear Medicine, 65, http://dx.doi.org/10.2967/jnumed.123.266164

Adebahr S; Althaus A; Scharl S; Strouthos I; Farolfi A; Serani F; Lanzafame H; Trapp C; Koerber SA; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Grosu AL; Kroeze SGC; Guckenberger M; Fanti S; Hruby G; Emmett L; Belka C; Schmidt-Hegemann NS; Henkenberens C; Aebersold DM; Wiegel T; Afshar-Oromieh A; Zamboglou C; Shelan M, 2024, 'The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy', European Journal of Nuclear Medicine and Molecular Imaging, 51, pp. 558 - 567, http://dx.doi.org/10.1007/s00259-023-06438-3

Trapp C; Aebersold DM; Belka C; Casuscelli J; Ceci F; Emmett L; Fanti S; Farolfi A; Grosu A-L; Guckenberger M; Henkenberens C; Hruby G; Koerber SA; Kroeze S; Peeken JC; Rogowski P; Scharl S; Shelan M; Spohn, SKB; Strouthos I; Unterrainer L; Vogel M; Wiegel T; Zamboglou, C; Schmidt-Hegemann N-S, 2024, '1443: Whole vs. hemi pelvis RT in patients with PSMA-positive nodal recurrence - a retrospective analysis', Radiotherapy and Oncology, 194, pp. S2436 - S2438, http://dx.doi.org/10.1016/s0167-8140(24)01834-6

Back to profile page